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INTRODUCTION 
 
Tuberculosis is caused by Bacteria, mycobacterium  tuberculosis. 
"Tuberculosis (TB) is the number one  infectious disease killer 
worldwide".   TB and  HIV  combination forms  the deadly synergy in 
India. It  leads to ‘unwanted outcomes "(10).  "HIV increases the risk of 
progression of latent TB infection to active TB disease thus increasing 
risk of death if not timely treated for both HIV and TB" .  TB is the most 
common  opportunistic infection and cause of mortality  among  PLHA 
patients. "Difficult to diagnose, treat and related to co-morbidity, pill 
burden, co-toxicity and drug interactions". Pulmonary infections have 
diverse presentations in the HIV patients, creating difficulty  in diagnosis 
and treatment. "The chest X ray  appearances of patients  presenting with 
pulmonary symptoms are frequently nonspecific"(6).  
              "It is estimated that  roughly  65-70% of  HIV patients  will 
develop tuberculosis in their lifetime". "50% of adult Indian population is 
infected with Mycobacterium tuberculosis"(6) .Those patients, early in the 
course of HIV infection would be expected to present similarly to Non 
HIV individuals with normal cellular immunity, while those late in the 
course of  HIV  may have a different presentation.. "India  ranks  second  
in the globe that contribute to 10-15% of   HIV-associated TB" 
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This study is being done  to diagnose Tuberculosis in early stage 
by studying the clinical, radiological and bacteriological features of 
pulmonary tuberculosis in HIV patients and plan for  further treatment, 
thereby preventing the spread of TB in the community by giving 
treatment as early as possible.  
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AIMS AND OBJECTIVES: 
 
¾ To evaluate the clinical , bacteriological and radiological 
pattern of pulmonary tuberculosis among  HIV seropositive 
patients in  Kilpauk medical college 
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REVIEW OF LITERATURE 
 
BACKGROUND: 
"There is increased  incidence of TB  in HIV positive patients". 
Both TB and HIV are called double trouble . "TB has a rapidly  
progressive and often a fatal course in HIV positive patients (4)   .Increased 
re-activation of latent PT occurs". "Mantoux test is false-negative. Smear 
may be negative and hence culture is vital. There are many atypical 
features". There is higher frequency of miliary tuberculosis, hilar 
adenopathy, extrapulmonary involvement. There is lower frequency of 
focal infiltrates and cavities. "We should diagnose TB as early as possible 
and we should treat both TB and HIV to prevent mortality" 
 
ETIOLOGY: 
It is a slender rod sometime showing branching filaments. “It is an 
acid fast bacilli, aerobic nonmotile, noncapsulated, nonsporing 
organism”.  “Transmission is by droplet nuclei of 1-5 μ in diameter 
which deposits in the alveoli”(4 
10 
 
 
Fig 1&2: STRUCTURE OF ACID FAST BACILLI & 
MYCOBACTERIA:
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HISTORICAL IMPORTANCE: 
          Tuberculosis lesions were seen in vertebrae of  Neolithic man in 
Europe and in Egyptian mummies(3). Skeleton remains to show 
prehistoric humans (4000 BC) had TB and "tubercular decay has been 
found in the spines of Egyptian  mummies from 3000-2400 BC" 
"Other names for tuberculosis are"(9) 
• Consumption -Tuberculosis seemed to consume people from 
within with its symptoms of bloody cough, fever, pallor, and long 
relentless wasting 
• Wasting disease 
• White plague  
• Phthisis and phthisis pulmonalis 
• "King's evil"(14) 
• Koch's Disease named after Robert Koch who discovered the 
tuberculosis bacilli ."The bacilli  was identified and described on 
March 24, 1882 by  Robert Koch. He received the Nobel Prize in 
1905 for this discovery"(3) 
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Fig 3: ROBERT KOCH 
 
 
Fig 4: Various names of Tuberculosis 
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EPIDEMIOLOGY: 
 
Fig 5: Global incidence of TB 
 
 
Fig 6: Global incidence of TB in HIV patients 
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Fig 7: Annual incidence of TB in India 
 
PATHOLOGY AND PATHOGENESIS: 
          80 to 90% of those infected with Mycobacterium tuberculosis have 
asymptomatic latent TB infection , with "only a 10% lifetime chance that 
a latent infection will progress to TB disease" (5). 
15 
 
 
 
 
Fig 8a : Pathogenesis of Tuberculosis 
 
           "However, if untreated, the death rate for these active TB cases is 
more than 50 percent". TB infection begins when the mycobacteria reach 
the pulmonary alveoli ,where they invade and replicate within alveolar 
macrophages. The primary site of  infection in the lungs is called the 
Ghon focus which is the subpleural focus in lower lobe 
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Fig 8b:  Pathogenesis of Tuberculosis 
 
 
Fig 8c:  Pathogenesis of Tuberculosis 
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             "Bacteria  picked up by dendritic  cells(3) , which do not allow 
replication, although these cells can transport the bacilli to local lymph 
nodes" . "Further spread is through the bloodstream to the more distant 
tissues and organs where secondary TB lesions can develop in lung 
apices, peripheral lymph nodes, kidneys, brain, and bones".  All parts of 
the body can be affected by the disease, though it rarely affects the heart, 
skeletal muscles , pancreas, nails, hairs and thyroid. 
 
Fig 9:  Histology of TB Granuloma 
 "Macrophages, T lymphocytes, B lymphocytes and fibroblasts are 
among the cells that aggregate to form a granuloma with lymphocytes 
surrounding the infected macrophages". 
Within the granuloma, "T lymphocytes(8) (CD4+) secrete cytokines 
such as interferon gamma which activates macrophages to destroy the 
18 
 
bacteria with which they are infected". T lymphocytes (CD8+) can also 
directly kill infected cells. Another feature of the granulomas of  human 
tuberculosis is the development of cell death, also called  the term 
necrosis, in the center of tubercles(12).                       
                 Severe form of TB disease is most common in infants and the 
elderly and is called miliary TB. "Disseminated tuberculosis defined as 
occurence in more than 2 noncontiguous organs, a fatality rate (2)  of upto 
20%, even with effective  treatment". 
 "Tissue destruction and necrosis are balanced by healing and 
fibrosis".  
During active disease, some of these cavities are joined to the air 
passages bronchi and this material can be coughed up. It contains living 
bacteria and can therefore pass on infection.  
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Fig 10:  Clinical features of TB in HIV 
DIAGNOSIS OF TUBERCULOSIS : 
SPUTUM AFB 
CHEST XRAY 
SPUTUM CULTURE( solids and liquids) 
MANTOUX TEST 
MOLECULAR METHODS ("GENE XPERT-RIF") 
INTERFERON GAMMA RELEASE ASSAY  
SEROLOGICAL METHODS 
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Fig 11:  Diagnosis of Tuberculosis 
 
Fig 12:  Diagnosis of TB in HIV patients 
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MICROBIOLOGICAL METHODS(11) 
 "A definitive diagnosis of tuberculosis can only be made by 
culturing Mycobacterium tuberculosis organisms from a specimen taken 
from the patient"(2) Sputum smears and cultures should be done for acid-
fast bacilli if the patient is producing sputum. "The preferred method for 
this is fluorescence microscopy (auramine-rhodamine staining), which is 
more sensitive than conventional Ziehl- Neelsen staining". 
MEAN TIME TO DIAGNOSE TB CASES 
GENEXpert -  90 minutes 
Sputum microscopy - 24 hrs 
Liquid culture - 18 days 
Solid culture medium - >32 days 
CONTENTS OF L-J MEDIUM: 
Coagulated hen's egg 
Asparagine (source of nitrogen) 
Malachite Green 
Glycerol(CO2 supply) 
MgSo4,Potassium disulphate 
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Fig 13:  Ziehl Neelson staining method 
            If no sputum is being produced, specimens can be obtained by 
inducing sputum, genital warts, a laryngeal swab, bronchoscopy with 
bronchoalveolar lavage, or fine needle aspiration of a collection (2). 
Routinely cultures have used the Löwenstein-Jensen (LJ), Kirchner, or 
Middlebrook media (7H9, 7H10, and 7H11). 
"MOLECULAR METHODS TO DIAGNOSE TB" 
"We can get the Results  within 100 mts, sensitivity increased upto 
92 % if 3 samples were tested"(16).  More useful for HIV with TB cases 
and to detect MDR TB cases(16) 
"IGRA  used to diagnose LTBI and is particularly useful in 
profoundly ill patients and those with severe malnutrition". "There are 
two in vitro tests to detect latent tuberculosis 
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QUANTIFERON TB GOLD and T SPOT-TB test 
 
Fig 14:  Immunodiagnosis of  LTBI 
The problem with IGRA is more expensive, skill needed, not 
suitable for serial testing. The advantage is high specificity and single 
patient visit enough. 
WHO banned use of serology to diagnose TB. 
"Mantoux skin test" 
 
Fig 21: Tuberculin test reading 
"Reading mantoux after 48-72 hrs" 
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Fig 15:  Rt upper lobe infiltration 
 
Fig 16: Bilateral extensive infiltrations due to TB 
 
Fig 17: Miliary TB in HIV patient 
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Fig 18:  Left Pleural Effusion 
 
Fig 19: Left upper lobe cavity with infiltrations  in HIV-TB coinfction 
 
Fig 20: Rt sided pneumothorax HIV-TB coinfction 
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TUBERCULIN SKIN TEST(13) 
 
Fig 22: TST vs IGRA 
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Fig  23:  Genexpert analyser 
"Clinical features of TB in HIV-infected persons Pulmonary TB" : 
      " In patients with mild immuno suppression, the clinical picture often 
resembles usual adult post‐primary pulmonary TB” the sputum smear is 
mostly positive  and the (1)chest X‐ray  typically shows unilateral or 
bilateral upper lobe infiltrates, cavity, pulmonary fibrotic strands, or 
volume loss. In persons with advanced HIV infection, disseminated  and  
extrapulmonary TB  are more common than in early HIV infection, and 
may be as common as pulmonary TB. "The most common forms of 
EPTB seen are lymphadenitis, pleural effusion, pericarditis, miliary 
disease and meningitis. "Of the two sputum specimens, one is collected 
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on the spot and the other is preferably an early morning sample collected 
at home by the patient".  
            Tuberculosis is classified into pulmonary or extrapulmonary, 
smear‐positive or smear‐negative disease . “A patient with one or two 
smears being positive for AFB out of the two sputum specimens 
subjected for smear examination by direct microscopy is smear positive 
pulmonary TB” (1). 
            “Patients with two smear negative on first occasion, persisting 
with symptoms following 10 - 14 days of  broad spectrum antibiotics 
(other than those having anti tubercular activity) and repeat sputum 
examination being negative with radiological abnormalities suggestive of 
active TB is diagnosed as having smear negative pulmonary 
tuberculosis". "Extra-pulmonary TB Tuberculosis of organs other than the 
lungs such as pleura, lymph nodes, intestine, genitor‐urinary tract, joint 
and bones, meninges of the brain etc., is called as extra‐ pulmonary TB 
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“ Pleural tuberculosis is classified as extra pulmonary”. 
 
Fig 24: Extrapulmonary TB symptoms 
COMPLICATION OF TUBERCULOSIS: 
TB PLEURISY 
PNEMOTHORAX 
DISSEMINATED TB 
EMPYEMA, PYOPNEMOTHORAX 
ASPERGILLOMA 
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HEMOPTYSIS 
PONCET DISEASE 
SCAR CARCINOMA 
RESPIRATORY FAILURE 
RIGHT VENTRICULAR FAILURE 
TB SPINE, TB ENTERITIS, TB LARYNGITIS. 
 
Treatment of TB in HIV-infected persons 
 "Treatment of  TB in HIV  is  same as treatment of Tuberculosis in 
persons without HIV infection".  First, all  HIV‐infected patients should 
be treated with a Category I or Category II(1) . “Directly Observed 
Treatment of quality‐assured anti‐TB drugs is the foundation of the 
internationally recommended  DOTS strategy, which maximizes cure by 
providing effective medicines and confirming that they are taken". 
"DOTS  is not just supervised swallowing; it is a mechanism to support 
the patient to complete the treatment. It is very important to ask history of 
previous anti - tuberculosis treatment to help define a case and to 
prescribe appropriate category of ATT. "There are significant drug   
interactions with the PIs and rifampicin". Protease inhibitors should not 
be used with rifampicin regimens due to hepatic enzyme inducing 
capacity of rifampicin, which may leads to Protease  levels sub 
therapeutic. " Rifabutin is a less potent inducer of CYP 3A4 liver enzyme 
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as compared to rifampicin, while being equally safe and effective for 
treatment of TB. 
 
 
Fig 25: DOTS  Therapy 
 
Fig 26a: Classification of ATT drugs 
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Fig 26b: Classification of ATT drugs 
INDICATION OF CORTICOSTEROIDS  IN TUBERCULOSIS: 
1. TB meningitis 
2. In seriously ill patients 
3. TB in serous sacs (peritonitis, pericarditis and pleural effusion to 
prevent fibrosis and adhesions and to facilitate absorption of fluid) 
4. Genito-urinary TB 
5. To control drug hypersensitivity reaction6. Rarely for regression of 
lymph nodes during chemotherapy 
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Human Immunodeficiency Virus: 
INTRODUCTION: 
        "In 1981, the first cluster of cases that we now call AIDS was 
recognized and reported". Nearly all of the early identified cases were in 
young homosexual men, but it was quickly learned that HIV infection 
could be transmitted by heterosexual contact and by blood transfer from 
infected to non infected individuals(7).  "In 1983 it was isolated from a 
patient with lymphadenopathy and in 1984 it was demonstrated clearly to 
be the causative agent of AIDS". India's first case of AIDS was 
reported in 1986 from Chennai. 
 
 
Fig 27: HIV Prevalence rate 
34 
 
 
EPIDEMIOLOGY 
INDIAN SCENARIO: 
¾ Number of people living with HIV: 2.5 million 
¾ India ranks 3rd in total number of HIV patients in world 
¾ Prevalence rate in adult male 0.43 % 
¾ Prevalence rate in adult female 0.29% 
¾ Prevalence in general population 0.36%. 
¾ Percentage of coverage of ART for prevention of mother to 
child transmission: <25%. 
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SCENARIO IN TAMILNADU IN 2014 
No of PLHA :135000 
No of CLHA :6700 
No of newinfections :2900 
No of AIDS related Deaths :8700 
HIV prevalence in different population is as follows: 
¾ Antenatal clinic attendees - 0.25%. 
¾  STD clinic attendees - 8%. 
¾ Female sex workers - 4.62%. 
¾ Men having sex with men - 5.60%. 
¾ Intra venous drug abusers - 24.2%. 
ETIOLOGY: 
"The etiologic agent of AIDS is Human Immunodeficiency Virus" 
. 
Fig 28:  Human Immunodeficiency Virus 
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LIFE CYCLE: 
 
Fig 29: Life cycle of HIV virus 
HIV- MODE OF SPREAD: 
 
Fig 30: Routes of transmission of HIV 
ATTACHMENT AND ENTRY: 
"The replication cycle of HIV begins with the high affinity binding 
of the gp 120 protein via a portion of its v1 region near the N terminus to 
its receptor on the host cell surface, the CD4 molecule".  
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"Once gp 120 binds to CD4, the gp 120 undergoes a 
conformational change that facilitates binding to one of a group of co-
receptors". "CCR5 and CXCR4. These 2 are major coreceptors" 
REVERSE TRANSCRIPTION AND INTEGRATION: 
        "Following binding of the envelope protein to the CD4 molecule", 
the virus is "uncoated" and the viral RNA is converted into 
complementary DNA (C-DNA) by virion associated reverse transcriptase 
enzyme. The C-DNA is transported to the host cell nucleus and 
eventually gets incorperated into the host cell chromosomes by virus 
specific integrase enzyme. 
 
TRANSCRIPTION, TRANSLATION AND REPLICATION: 
        The integrated DNA is transcribed into messenger RNA (mRNA) 
which comes out into cytoplasm and viral proteins are synthesized using 
protein synthesizing machinery and raw material from the host cell. Some 
of the viral proteins are synthesized as polyproteins that are eventually 
cleared by the proteinase enzyme. 
MATURATION AND RELEASE: 
       Newly synthesized progeny RNA and proteins are packaged together 
and the newly formed virus particles are released from the infected cell 
by the budding process(15). 
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CLASSIFICATION OF HIV INFECTION - WHO  
 
 
 
ANTI RETRO VIRAL DRUGS: 
           HAART is the cornerstone of management of HIV , Early 
initiation is the key to prevent morbidity and mortality. 
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FIG 31: Site of action of HAART 
 
Fig 32: Classification of  ART 
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             "Early Initiation of ART in HIV-infected TB patients ART 
reduces both the TB case fatality rates, the incidence of TB, and the 
incidence of recurrent TB."  
 
"Only patients with isolated pulmonary TB and CD4 count >350 
would not immediately be eligible for HAART".  "In the absence of 
ART, TB therapy alone does not significantly increase CD4 cell counts, 
nor significantly decrease HIV viral load among HIV‐infected TB 
patients (1) . “The use of ART in  patients with TB can lead to  reductions 
in HIV viral load, immunologic reconstitution, decrease in AIDS defining 
illness, and reduces the  mortality"..zidovudine  used when HB >9 gm, 
Stavudine used when HB less than 9gm. Lamivudine always used as 
added dug .zidovudine dose is 300 mg BD , Lamivudine dose is 150 mg 
BD. "Use rifabutin as substitution for rifampicin. "When switching from 
EFV to NVP, no lead‐in dose is required”.  
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Fig 33:  NACO Guidelines 
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IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME 
“Slight worsening of symptoms and signs of  TB or radiological 
deterioration after the initiation of HAART, (16)even after a reduction in 
HIV load (>1 log10 copies/μl) and immunological recovery, is known as 
IRIS”                           
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Fig 34:  Immunology of IRIS in HIV- TB coinfection 
 
PATHOPHYSIOLOGY OF IRIS: 
Poorly understood, mostly due to release of cytokines interferon 
gamma or lack of inhibitory immune responses. 
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RISK FACTORS FOR IRIS: 
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TYPES OF IRIS: 
 
Fig 35: Various types of IRIS 
A. ASYMPTAMATIC PATIENT STARTED ON ART 
B. MILIARY TB AFTER ART 
C. RESOLUTION AFTER ANTI TB DRUGS 
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D. MILIARY TB OF THE PATIENT WITH BASELINE 
E. RESOLUTION AFTER 1 MONTH OF ANTI TB DRUGS 
F. FLARE UP OF LESION AFTER HAART (PARADOXICAL    
WORSENING) 
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MATERIALS AND METHODS: 
 
Study group  : HIV Seropositive with Tuberculosis patients attending  
ART clinic and  those patients admitted in the medical ward  Govt 
Kilpauk Medical College Hospital 
 
Study design : Descriptive study {Cross sectional study} 
 
Place Of Study : Govt. kilpauk medical college    
 
Duration of study :  8 months 
 
Conflict of interest  :  Nil 
 
Colloborating Depts:  Micro-Biology, Bio-Chemistry, Radiology, 
Chest Medicine. 
 
Sample size N = Z²{P*Q} / l² 
 
Z; with 95% confidence interval z value is taken as 1.96 
 
P;Prevalence  of tuberculosis in HIV patients is 20% 
 
Q; 100-p 
 
L; relative precision taken is 50% 
 
So applying these variables in the formula  sample size is 64  
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INCLUSION CRITERIA: 
Patients with  symptoms  like fever, cough with expectoration 
lasting for more than two weeks, loss of appetite and loss of weight who 
are found to have HIV seropositive with tuberculosis. 
 
Patients with Tuberculous Pleural Effusion were included in the 
study. 
 
EXCLUSION CRITERIA: 
 
Patients who are suffering from Extra-pulmonary  Tuberculosis like 
TB Pericarditis, TB meningitis, TB abdomen, isolated TB 
lymphadenopathy, Potts Spine   and other seriously ill patients.   
 
 No consensus among all the three independent observers regarding 
the X-Ray features of Tuberculosis   infection. 
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METHODOLOGY 
 
HIV Seropositive  Patients  attending  ART Clinic and medical 
wards  of  kilpauk medical college were screened for Tuberculosis 
infection. Among 150 HIV seropositive patients screened for 
tuberculosis, 64 of them were found to have inection. 
 
A brief  History of illness was taken from the seropositive 
individuals and these patients were subjected to the following further 
investigations that include Complete blood count, Liver Function Test, 
Renal function test, Sputum Microscopic Examination for Acid Fast 
Bacilli,  Chest X-Ray PA view, Mantoux test (Intradermal tuberculin skin 
test), CD-4+ cell count. CBC , RFT, LFT  are done using  the  
conventional laboratory methods. 
 
 Patients were considered to be suffering from Tuberculosis if, 
1. Sputum is positive for AFB. 
2.  The Mantoux test  reading shows induration above 5mm. 
3. X-Ray features were suggestive of Tuberculosis. Since there 
is a high reporting of  both inter-observer and intra-observer variations, 
opinions were obtained from three persons separately - a general 
physician, a thoracic physician and a radiologist and their Tuberculosis 
status confirmed. 
 SAFETY 
¾ No harm done to the patient 
¾ No extra expenses to the patients 
¾ Informed consent will be obtained and follow up will be done 
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RESULTS 
 
The collected data was analysed with SPSS 16.0 version. To 
describe about the data descriptive statistics frequency analysis, 
percentage analysis were used for categorical variables and the mean & 
S.D were used for continuous variables. To find the significant difference 
between the bivariate samples in Independent groups the Unpaired 
sample t-test was used. To find the significance in categorical data Chi-
Square test was used. In both the above statistical tools the probability 
value .05 is considered as significant level.  
 
Using this computer software,multiple variables like mean range 
percentages, standard deviation, chi square and p value etc are used to test 
for the statistical significance of the study. A p value of  less than 0.05 
denotes significant relationship. 
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Age range with Gender
Female Male
Table 1 - Age distribution : 
Age range 
Total no. of patients 
 Percentage (%) 
Female Male 
Upto 30yrs 8 0 8 
31 - 40 yrs 4 38 42 
>40yrs 3 11 14 
 
Total 15 49 64 
 
The age of  subjects ranged from 21-46. The mean age was 
35.48.minimum age is 21 for female and 31 for male , maximum age of 
patient in this study for both male and female  is 46.  
 
 
 
 
 
 
Fig 36 : Comparison of Age distribution with Gender 
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Table 2 - Sex distribution : 
Sex Total no. of patients Percentage(%) 
Female 15 23.4 
Male 49 76.6 
Total 64 100.0 
 
 Out of the  64 patients, 76.6% (49 patients) were  males, 23.4%(15 
patients) were females.  
 
 
Fig 37 : Distribution of Gender 
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Table 3 -  Distribution of patients according to Occupation 
Occupation Total no. of Patients Percentage (%) 
Agriculture 9 14.1 
Business 8 12.5 
Driver 31 48.4 
House wife 13 20.3 
SL 3 4.7 
Total 64 100.0 
 
Out of  64 patients driver was  the most common occupation 
48.4%, in which CD4 count <350 is 23 members 
 
Fig 38 : Distribution  of  Occupation  among  study population 
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Table 4 -  Distribution of patients according to Symptoms : 
Symptoms Total no. of Patients Percentage (%) 
Cough 52 81.3 
Fever 41 64.1 
Loss of wt/Apettite 48 75.0 
 
Among the symptoms cough was  the most common symptom, out 
of 64 patients  52 patients had cough. next  one is loss of weight and 
appetite. 
 
Fig 39 : Distribution of Symptoms among study population 
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Table 5 -  Mantoux test result distribution  : 
Mantoux test Total no. of Patients Percentage (%) 
< 5 46 71.9 
> 5 18 28.1 
Total 64 100.0 
 
Among the study group, 46 Patients(71.9%)  had Mantoux <5 mm, 
18 patients had Mantoux >5 mm(28.1%).  
 
 
Fig 40 : Distribution of Mantoux test results among study population 
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Table 6 -  Sputum AFB result distribution  : 
Sputum AFB Total no. of Patients Percentage (%) 
Negative 51 79.7 
Positive 13 20.3 
Total 64 100.0 
 
The proportion of  sputum positivity was found to be higher in 
those patients with CD4 count >350   , 10 Patients.  In Patients with  CD4 
count < 350 , sputum positivity  was present only in 3 patients 
 
Fig 41 : Distribution of Sputum AFB results among study population 
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Table 7 -  CD4 Count result distribution  : 
CD4 count Total no. of Patients Percentage (%) 
> 350 20 31.3 
< 350 44 68.8 
Total 64 100.0 
 
44  patients  had  CD 4 Count <350 (Male 36, Female  8 patients), 
20 patients had CD4 count >350 (Male  13, Female  7 patients) 
 
Fig 42 : Distribution of CD4count results among study population 
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Table 8a -  Distribution of Patients according to X ray findings : 
 
X ray findings Upper lobe Lower lobe 
Cavity 5 (7.8%) 4 (6.3%) 
Infiltration 21 (32.8%) 22 (34.4%) 
None 38 (59.4%) 38 (59.4%) 
 
In chest x ray upper lobe lesion seen in 26 patients (5 cavity and 21 
infiltration), in which CD4 count <350 was 16 patients. lower lobe lesion 
in  26 patients (4 cavity and 22 infiltrations). Pleural effusions present in 
15 patients(23.4% of 64 patients) 
 
Fig 43 : Distribution of X ray findings among study population 
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Table 8b -  Distribution of Patients according to X ray findings : 
 
X ray findings Pleural Effusion Miliary Mottling 
No 49 (76.6%) 57 (89.1%) 
Yes 15 (23.4%) 7 (10.1%) 
 
Miliary mottling seen in 7 patients among 64 study group, pleural 
effusion were seen in 15 patients 
 
Fig 44 : Distribution of X ray findings among study population 
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Table 9 -  Comparison of Age distribution with CD4 count : 
Age range 
CD4 
Total > 350 < 350 
 <30   4 4 8 
 (20.0%) (9.1%) (12.5%) 
31-40  15 27 42 
 (75.0%) (61.4%) (65.6%) 
>40   1 13 14 
 (5.0%) (29.5%) (21.9%) 
Total  20 44 64 
 100.0% 100.0% 100.0% 
            
p value - 0.064 (not significant) 
31 to 40 years age range had more no of patients with CD4 count 
<350, 27 patients among 44, surprisingly CD 4 count > 350 also seen in 
31- 40 yrs group.   
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Fig 45 : Comparison of Age with CD4 count among study population 
63 
 
Table 10 -  Comparison of Sex distribution with CD4 count : 
Sex 
CD4 
Total > 350 < 350 
 Female  7 8 15 
     ( 35.0%) (18.2%) (23.4%) 
Male  13 36 49 
 (65.0%) (81.8%) (76.6%) 
Total  20 44 64 
 100.0% 100.0% 100.0% 
p value - 0.141 (not significant) 
36 male patients and 13 female patients had CD4 count <350 
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Fig 46 : Comparison of  Gender with CD4 count among study 
population 
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Table 11 -  Comparison of Mantoux test with CD4 count : 
Mantoux test 
CD4 
Total > 350 < 350 
  < 5  8 38 46 
 (40.0%) (86.4%) (71.9%) 
> 5  12 6 18 
 (60.0%) (13.6%) (28.1%) 
Total  20 44 64 
 100.0% 100.0% 100.0% 
p value - 0.000 (highly significant) 
Mantoux >5 mm seen in 18 patients, out of that 12 patients comes 
under CD4 Count >350, only 6 patients with CD4 <350  had mantoux >5 
mm 
 
Fig 47 : Comparison of Mantoux with CD4 count among study 
population 
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Table 12 -  Comparison of Sputum AFB with CD4 count : 
 
Sputum AFB 
CD4 
Total > 350 < 350 
 Negative  10 41 51 
  (50.0%) (93.2%) (79.7%) 
Positive  10 3 13 
  (50.0%) (6.8%) (20.3%) 
      Total  20 44 64 
 100.0% 100.0% 100.0% 
p value -0.000(highly significant) 
Sputum  was positive in 13 patients in which 10 patients were 
comes under CD4 count more than 350,only 3 patients positive for 
sputum in CD4 count <350 
 
Fig 48 : Comparison of Sputum AFB with CD4 count among study 
population 
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Table 13a -  Comparison of X ray findings with CD4 count : 
 
X ray  findings 
Upper lobe Lower lobe 
> 350 < 350 > 350 < 350 
Cavity 3 (15%) 2 (4.5%) 3 (15%) 1 (2.3%) 
Infiltration 5 (25%) 16 (36.4%) 6 (30%) 16 (36.4%)
None 12 (60%) 26 (59.1%) 11 (55%) 27 (61.4%)
 
In CD 4 count <350 patients cavity comparitively less in both 
upper lobes and lower lobes. 
Upper lobe lesions vs CD4 count, p value -0.291 (not significant) 
Lower lobe lesions vs CD4 count , p value- 0.148(not significant) 
 
Fig 49 : Distribution of X ray findings with CD4 count among study 
population 
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Table 13b -  Comparison of X ray findings with CD4 count : 
X ray 
findings 
Pleural effusion Miliary mottling 
> 350 < 350 > 350 < 350 
No 15 (75%) 34 (77.3%) 20 (100%) 37 (84.1%)
Yes 5 (25%) 10 (22.7%) 0 (0%) 7 (15.9%) 
 
Military mottling vs CD4 count p value - 0.059 (significant) 
Pleural effusion  vs CD4 count , p value -0.842(not significant) 
 
Fig 50 : Distribution of Xray findings with CD4 count among study 
population 
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Table 14 -  Comparison of results of Sputum AFB with Mantoux test: 
 
   
 
 
Sputum AFB 
Mantouxtest 
Total   < 5 > 5 
 Negative  40 11 51 
 (87.0%) (61.1%) (79.7%) 
Positive  6 7 13 
 (13.0%) (38.9%) (20.3%) 
Total  46 18 64 
 100.0% 100.0% 100.0% 
p value -0.021(significant) 
 
7 patients  with mantoux  >5 mm and  6  patients with mantoux  <5 
mm had sputum positivity  
 
Fig 51 : Comparison of  Mantoux test with Sputum AFB among 
study population 
Table 15 -  Comparison of results of Symptoms with CD4 count : 
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Symptom CD4 count 
<350                                  >350 
None 2 (10%) 2 (4.5%) 
Cough 4 (20%) 15 (34.1%) 
Fever 5 (25%) 3 (6.8%) 
Both 9 (45%) 24 (54.5%) 
p value - 0.141 (not significant) 
Symptoms both cough and fever were more seen in CD4 count > 
350( 54.5%)  
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Fig 52 : Comparison of Symptoms with CD4 count among study 
population 
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Table 16 -  Comparison of results of Upper lobe with Symptoms : 
Symptoms None Cough Fever 
X ray findings 
Cavity 0 1 1 
Infiltration 3 7 3 
None 1 11 4 
p value - 0.539 (not significant) 
Among  Upper lobe lesions commonest symptom was cough 
followed by  fever 
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Fig 53 : Comparison of Upper lobe findings with symptoms among 
study population 
71 
 
Table 17 -  Comparison of results of Lower lobe with Symptoms: 
Symptoms None Cough Fever 
X ray findings 
Cavity 1 2 0 
Infiltration 1 7 1 
None 2 10 7 
 
p value - 0.356 (not significant) 
In lower lobe lesion  cough was the main symptom followed by 
fever 
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Fig 54 : Comparison of Lower lobe findings with symptoms  among 
study population 
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Table 18 -  Comparison of results of Pleural effusion with Symptoms: 
Symptoms None Cough Fever 
X ray findings 
Absent 3 15 5 
Present 1 4 3 
 
p value -0.792 (not significant) 
15 patients with pleural effusion,  commonest symptom was cough  
followed by fever 
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Fig 55 : Comparison of Pleural effusion with symptoms result among 
study population 
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Table 19 -  Comparison of results of Miliary mottling with 
Symptoms: 
Symptoms None Cough Fever 
X ray findings 
Absent 4 17 8 
Present 0 2 0 
 
p value - 0.556 ( not significant) 
All 7 patients had cough and loss of wt and appetite, 5 patients had 
fever 
 
Fig 56 : Comparison  of  results of  Miliary mottling with Symptoms 
among study population 
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Table 20 - Comparison of results of  Upper lobe findings with 
Sputum AFB: 
Sputum AFB Negative Positive 
X ray findings 
Cavity 3 2 
Infiltration 18 3 
None 30 8 
 
p value 0.431 (not significant) 
2  patients with upper lobe cavity and 3 patients with  upper lobe 
infiltrations had sputum positivity 
 
Fig 57 : Comparison of results of  Upper lobe findings with Sputum 
AFB among study population 
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Table 21 - Comparison of results of  Lower lobe findings with 
Sputum AFB: 
 
Sputum AFB Negative Positive 
X ray findings 
Cavity 3 1 
Infiltration 18 4 
None 30 8 
 
p value - 0.938 (not significant) 
 1 patient  with  lower lobe cavity and 4 patients with  lower lobe 
infiltrations had  sputum positivity 
 
Fig 58 : Comparison of results of  Lower lobe findings with Sputum 
AFB among study population 
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Table 22 - Comparison of results of Pleural effusion with Sputum 
AFB : 
Sputum AFB Negative Positive 
X ray findings 
Absent 38 11 
Present 13 2 
 
p value 0.443 (not significant) 
Among 15, Two pleural effusion cases had sputum positivity.  
 
 
Fig 59: Comparison of results of Pleural effusion with Sputum AFB 
among study population 
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Table 23 - Comparison of results of Miliary mottling with Sputum 
AFB : 
 
Sputum AFB Negative Positive 
X ray findings 
Absent 44 13 
Present 7 0 
 
p value - 0.157 (not significant) 
No military mottling was there in sputum positive patients  
 
 
Fig 60 : Comparison of results of  Miliary mottling with Sputum AFB 
among study population 
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DISCUSSION 
In this  study,  64  patients with HIV infection  was having  TB 
coinfection. Out of these 64 patients, 76.6% (49 patients) were males, 
23.4%(15 patients) were females. Out of 64 patients driver was the most 
common occupation 48.4%, in which CD4 count <350 was 23 members. 
Among the symptoms cough was the most common symptom, out of 64 
patients  52 patients had cough. next  one is loss of weight and appetite. 
The proportion of sputum positivity was found to be higher in those 
patients with CD4 count >350   , 10 Patients.  Patients with  CD4  count < 
350  sputum positivity  was present only in 3 patients. patients had CD4  
count  range of minimum of 116 and maximum of 510, mean CD4 count 
is 295.19,mean count in male 289.57, in females mean count is 313.53. 
44 patients had  CD 4 Count <350 (Males - 36, Females - 8), 20 patients 
had CD4 count >350 (Males-13, Females -7). In chest x ray upper lobe 
lesion were seen in 26 patients( 5 cavity and 21 infiltration), in which 
CD4 count <350 in 16 patients. Lower lobe lesion were seen in 26 
patients (4 cavity and 22 infiltrations). Pleural effusions were present in 
15 patients (23.4% of 64 patients). Mantoux >5 mm seen in 18 patients, 
out of that 12 patients comes under CD4 Count >350, only 6 patients with 
CD4 <350  had mantoux >5 mm.   
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       Sputum positivity was 20.3 %among 64 patients.  There is no much 
difference in mantoux positivity with sputum positivity in our study, 7 
patients with >5 mm and 6 patients with <5 mm had sputum positivity. 
Symptoms both cough and fever were more seen in CD4 count > 350, 
54.5% with CD4 >350 and  45 % with <350 , only minimal difference 
was there regarding to symptoms. Two pleural effusion cases had sputum 
positivity. No military mottling had sputum positivity. 4 miliary mottling 
had history of Diabetes. 8 Diabetes patients had pleural effusion.  27 
patients were diabetic in which 11 had upper lobe lesion ( 1 cavity ,10 
infiltrations)…in diabetic 10 patients had lower lobe lesions. No military 
mottling was there in sputum positive patients , mostly it was there in 
CD4 count <350.  
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LIMITATIONS OF THE STUDY 
 
Sample size was achieved with 10% absolute precision, hence the 
results of the study will have wide variability. Due to limited resources 
and practical constraints this study is being carried out with a small 
sample size. Thus the appropriate representation of the population and 
better outcomes could be attained by increasing the sample size 
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SUMMARY AND CONCLUSION 
 
"Incidence of TB, HIV and HIV-TB is higher in India", this study 
is absolutely justified. Incidence of  Tuberculosis in In our country  is 185 
per lakh population; "there are 25 to 30 lakhs people living with HIV", 
out of these 55 to 60% will develop Tuberculosis  in their life .  
 
a) By studying the clinical, radiological and bacteriological features 
of pulmonary tuberculosis in HIV patients, we can diagnose the 
tuberculosis  early and can plan for  further treatment.  
b) "We can prevent the spread of TB in the community by giving 
treatment as early as possible" 
 
1.  Majority of patients were in the age group 30-40 
 years(42%).  
 
2.  Out of 64  people 76.6% were males 23.4% females.  
3. Most common presenting symptoms were cough (81.3), loss 
  of wt and appetite (75%)  
4. Among x-ray findings Unilateral upper zone infiltrative 
lesions were more common than lower zone infiltrations in 
sputum positive patients.  
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5. Sputum positivity was seen in 20.3%% of patients.  
6. Mean CD4 count in this study was 295.19.  313.53 in 
females, 289.57 in males 
7.  Most of the patients (68%) had CD4 counts <350 cells/μl.  
8. 100% of miliary TB had  sputum negativity, all had CD4 
count <350 
9. 27 patients are Diabetic, out of that 4 patients had military 
TB, 8 Patients had pleural effusion. 20 patients had CD4 
count <350. Lower lobe lesions leen in 10 patients 
10. Mantoux >5 mm were seen in 18 patients out of which 12 
patients had CD4 Count >350 
11. In this study there was highly significant correlation  
between  mantoux vs CD4 count and sputum AFB vs CD4 
count present 
12. In this study there was significant correlation between  
sputum AFB vs mantoux and military mottling vs CD4 count 
present 
13. On comparing diabetes with lower lobe lesions , there was 
significant correlation present, p-value was 0.022. 
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14. Among the symptoms cough had significant correlation with 
CD4 count , p value was 0.025 
 
“Thus, a high level of clinical suspicion is required in diagnosis of 
TB in HIV infected especially when they are in the later stages of disease 
which is indicated by CD4 counts <350 cells/μl.” Tuberculosis is said to 
be  the commonest opportunistic infection in patients with HIV/ AIDS. 
The most common symptom in these patients was cough and 
expectoration, followed by fever and weight loss.  
Hence, the diagnosis of tuberculosis has to be suspected in HIV positive 
persons irrespective of the type, site and extent of radiological lesions. 
Further, since tuberculosis could be present even in persons with a normal 
chest X-ray, the presence of symptoms warrants detailed investigations.  
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LIST OF ABBREVATIONS USED 
TB TUBERCULOSIS 
HIV HUMAN IMMUNODEFIENCY VIRUS 
 
AFB ACID FAST BACILLI 
ATT ANTI TUBERCULOUS TREATMENT 
ART ANTI RETROVIRAL THERAPHY 
HAART HIGHLY ACTIVE ANTIRETROVIRAL THERAPHY 
AIDS ACQUIRED IMMUNODEFICIENCY SYNDROME 
EPTB EXTRAPULMONARY TUBERCULOSIS 
IRIS IMMUNE RECONSTITUTION  INFLAMMATORY 
SYNDROME 
DOTS DIRECTLY OBSERVED TREATMENT 
SHORTCOURSE THERAPHY 
CPT COTRIMOXAZOLE PREVENTIVE THERAPHY 
CXR CHEST XRAY 
MX MANTOUX 
PLHIVA PEOPLE LIVING EITH HIV AND AIDS 
CBC COMPLETE BLOOD COUNT 
FACS FLOURESCENSE ACTIVATED CELL SORTING 
RNA RIBO NUCLIC ACID 
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STUDY PROFORMA 
NAME :                                                             DIAGNOSIS: 
 
AGE/SEX: 
IP/OP NO: 
MARITAL STATUS: 
EDUCATIONAL STATUS: 
OCCUPATION: 
WHO STAGE: 
ADDRESS: 
DETAILS OF PRESENT ILLNESS: 
¾ Cough with expectoration  > 2 weeks: Y/N 
¾ Evening rise of temperature: Y/N 
¾ Loss of wt and appetite: Y/N 
 
PAST HISTORY: DM-2 /  SHT / TB / CVA  /BA/ EPILEPSY,  
DRUG HISTORY; 
HISTORY OF PREVIOUS ATT, ANTI RETROVIRAL DRUGS FOR 
HIV 
FAMILY HISTORY:   DM-2/ SHT/  TB/ BA/ CAD/ EPILEPSY 
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PERSONAL HISTORY: SMOKING: PACK YEARS 
ALCOHOL:Y/N , DURATION 
IV DRUG ABUSE: 
DIET: VEG/NONVEG 
EXPOSURE TO STD: 
GENERAL EXAMINATION: 
- Built & nourishment: 
- Height:                   weight:                     BMI: 
- P/I/CY/CL/LN/PE 
         VITAL SIGNS :  
- A) PULSE RATE       B) BLOOD PRESSURE  
- C) TEMPARATURE D) RESPIRATORY RATE 
Cutaneous stigmata of  TB   : 
Tinea versicolor, Lupus vulgaris, Erythema nodosum, 
Scrofuloderma, Healed sinus and scars  , cold abscess 
Eyes : phylecten, choroid tubercles. 
SYSTEMIC EXAMINATION: 
RESPIRATORY SYSTEM: 
INSPECTION: 
TRACHEAL POSITION, APICAL IMPULSE, CHEST WALL 
DEFORMITY,  
¾ PALPATION 
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¾ PERCUSSION 
¾ AUSCULTATION 
Breath sounds, added sounds 
CARDIOVASCULAR SYSTEM: 
ABDOMINAL SYSTEM: 
CENTRAL NERVOUS SYSTEM: 
INVESTIGATIONS:  
 CBC – TC, DC, ESR, Hb, Platelet count. 
 BIOCHEMISTRY:- 
                              - RBS 
                               -B.Urea, S.Creatinine., 
                               -Serum electrolytes( Na, K, ) 
 URINE ROUTINE EXAMINATION---sugar,albumin, deposits 
 CHEST X-RAY 
 ECG 
 LIVER FUNCTION TEST (S.BILIRUBIN, SGOT, SGPT,SAP, 
TOTAL PROTEIN, ALBUMIN, GLOBULIN) 
 MANTOUX TEST AND CD4 COUNT 
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Age Sex 
Occu
patio
n Cough Fever 
Loss of 
wt & 
appetite DM 
Manto
ux test 
Sputum 
AFB CD4 
CD4 
Count 
Upper 
lobe 
Lower 
lobe 
Pleura
l 
effusi
on 
Miliary 
mottlin
g 
Age 
Range 
22 Female HW Present Present Absent No > 5 Positive > 350 426 Cavity None No No 
Upto 
30 yrs 
24 Female HW Absent Present Absent No > 5 Negative > 350 410 Infiltration None Yes No 
Upto 
30 yrs 
23 Female Agri Present Absent Absent No > 5 Positive > 350 486 None 
Infiltrati
on No No 
Upto 
30 yrs 
37 Female HW Absent Present Present No < 5 Positive > 350 421 None 
Infiltrati
on No No 
31 - 
40 yrs 
26 Female HW Present Present Absent No < 5 Negative < 350 164 None None Yes No 
Upto 
30 yrs 
36 Female HW Absent Present Absent No < 5 Negative < 350 330 None None No No 
31 - 
40 yrs 
45 Female HW Present Present Present Yes < 5 Negative < 350 210 Infiltration None No No 
Above 
40 yrs 
28 Female Agri Present Present Present Yes > 5 Negative < 350 178 None None No Yes 
Upto 
30 yrs 
38 Female HW Absent Absent Present Yes < 5 Positive > 350 362 None Cavity Yes No 
31 - 
40 yrs 
46 Female HW Present Absent Present Yes < 5 Negative < 350 286 Infiltration None No No 
Above 
40 yrs 
25 Female HW Absent Present Present No > 5 Positive > 350 358 Cavity None Yes No 
Upto 
30 yrs 
31 Female HW Absent Absent Present No > 5 Negative > 350 434 Infiltration None No No 
31 - 
40 yrs 
21 Female HW Present Present Present Yes < 5 Negative < 350 220 None None No No 
Upto 
30 yrs 
45 Female HW Present Present Present Yes > 5 Negative < 350 142 None None Yes No 
Above 
40 yrs 
29 Female HW Absent Present Present No < 5 Positive < 350 276 None None No No 
Upto 
30 yrs 
43 Male Agri Present Absent Present Yes < 5 Negative < 350 336 Cavity None No No 
Above 
40 yrs 
32 Male 
Busin
ess Present Present Present Yes < 5 Negative < 350 310 Infiltration None No No 
31 - 
40 yrs 
41 Male Driver Present Present Absent No < 5 Negative < 350 220 None 
Infiltrati
on Yes No 
Above 
40 yrs 
37 Male 
Busin
ess Present Present Present Yes < 5 Negative < 350 168 None 
Infiltrati
on No Yes 
31 - 
40 yrs 
40 Male Driver Present Present Present No < 5 Negative < 350 220 None 
Infiltrati
on Yes No 
31 - 
40 yrs 
42 Male Agri Present Present Present No < 5 Negative < 350 310 Cavity None No No 
Above 
40 yrs 
40 Male Driver Present Present Absent Yes < 5 Positive > 350 406 None 
Infiltrati
on No No 
31 - 
40 yrs 
41 Male Driver Present Present Present Yes > 5 Negative > 350 510 None 
Infiltrati
on No No 
Above 
40 yrs 
39 Male Agri Present Present Present Yes < 5 Negative < 350 116 None None No Yes 
31 - 
40 yrs 
31 Male 
Busin
ess Absent Present Present No < 5 Negative < 350 169 Infiltration None Yes No 
31 - 
40 yrs 
33 Male 
Busin
ess Present Absent Present No > 5 Positive > 350 386 Infiltration None No No 
31 - 
40 yrs 
44 Male SL Present Absent Present Yes < 5 Negative < 350 260 None None No No 
Above 
40 yrs 
38 Male Driver Present Present Present No < 5 Negative < 350 276 Infiltration None No No 
31 - 
40 yrs 
32 Male 
Busin
ess Present Present Present No < 5 Positive > 350 359 None None No No 
31 - 
40 yrs 
37 Male Driver Present Present Present Yes > 5 Negative > 350 391 None Cavity Yes No 
31 - 
40 yrs 
31 Male Driver Absent Absent Present No < 5 Negative < 350 286 Infiltration 
Infiltrati
on No No 
31 - 
40 yrs 
34 Male 
Busin
ess Present Present Absent No > 5 Positive > 350 416 None None No No 
31 - 
40 yrs 
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41 Male Driver Present Present Present Yes < 5 Positive < 350 310 None None No No 
Above 
40 yrs 
36 Male Driver Present Present Absent No < 5 Negative < 350 136 None None No No 
31 - 
40 yrs 
42 Male Agri Present Present Present No < 5 Negative < 350 220 Infiltration None No Yes 
Above 
40 yrs 
31 Male 
Busin
ess Absent Absent Present No > 5 Positive < 350 260 Infiltration None No No 
31 - 
40 yrs 
38 Male Driver Present Present Present Yes < 5 Negative < 350 220 None 
Infiltrati
on Yes No 
31 - 
40 yrs 
35 Male Driver Present Present Present Yes > 5 Negative < 350 322 Infiltration None Yes No 
31 - 
40 yrs 
38 Male Agri Present Present Present Yes < 5 Negative < 350 164 Infiltration None No Yes 
31 - 
40 yrs 
37 Male Driver Present Absent Present Yes < 5 Negative > 350 398 None Cavity Yes No 
31 - 
40 yrs 
44 Male Driver Present Present Present No < 5 Negative < 350 282 None 
Infiltrati
on No No 
Above 
40 yrs 
32 Male Driver Present Present Absent No > 5 Negative < 350 294 None None No No 
31 - 
40 yrs 
35 Male SL Present Absent Present No < 5 Negative < 350 320 None 
Infiltrati
on No No 
31 - 
40 yrs 
37 Male Driver Present Present Present Yes < 5 Negative < 350 286 None 
Infiltrati
on No No 
31 - 
40 yrs 
41 Male Driver Present Absent Present Yes < 5 Negative < 350 256 Infiltration None Yes No 
Above 
40 yrs 
36 Male Driver Present Absent Present No < 5 Negative < 350 232 None 
Infiltrati
on No No 
31 - 
40 yrs 
31 Male 
Busin
ess Present Present Absent No > 5 Negative > 350 402 Cavity None No No 
31 - 
40 yrs 
33 Male Driver Present Absent Present No < 5 Negative < 350 310 Infiltration None No No 
31 - 
40 yrs 
38 Male Driver Present Present Present No < 5 Negative < 350 294 None 
Infiltrati
on No No 
31 - 
40 yrs 
43 Male Agri Present Present Absent No < 5 Negative < 350 210 None 
Infiltrati
on No No 
Above 
40 yrs 
35 Male Driver Present Absent Present No < 5 Negative < 350 160 None 
Infiltrati
on No No 
31 - 
40 yrs 
37 Male Driver Present Absent Present No < 5 Negative < 350 152 None 
Infiltrati
on No Yes 
31 - 
40 yrs 
46 Male Driver Present Present Present Yes > 5 Negative < 350 390 Infiltration 
Infiltrati
on No No 
Above 
40 yrs 
36 Male Driver Absent Present Present Yes > 5 Negative > 350 370 Infiltration None No No 
31 - 
40 yrs 
32 Male Driver Present Absent Present No < 5 Negative > 350 402 None None No No 
31 - 
40 yrs 
40 Male Agri Present Absent Absent Yes < 5 Negative < 350 220 None Cavity No No 
31 - 
40 yrs 
35 Male Driver Present Present Present No < 5 Negative > 350 426 None 
Infiltrati
on No No 
31 - 
40 yrs 
31 Male Driver Present Absent Present Yes < 5 Negative < 350 258 Infiltration None No No 
31 - 
40 yrs 
36 Male Driver Present Absent Present No < 5 Negative < 350 222 Infiltration None No Yes 
31 - 
40 yrs 
35 Male SL Present Present Absent No > 5 Positive > 350 362 Infiltration 
Infiltrati
on No No 
31 - 
40 yrs 
31 Male Driver Absent Present Absent Yes < 5 Negative > 350 382 None None No No 
31 - 
40 yrs 
33 Male Driver Present Absent Present No < 5 Negative < 350 399 None 
Infiltrati
on No No 
31 - 
40 yrs 
34 Male Driver Present Absent Absent Yes < 5 Negative < 350 172 Infiltration None Yes No 
31 - 
40 yrs 
31 Male Driver Present Absent Present No < 5 Negative < 350 219 None 
Infiltrati
on Yes No 
31 - 
40 yrs 
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KEYS TO MASTER CHART: 
 
SL  -  SKILLED LABOUR 
HW  - HOUSE WIFE 
Y  - YES 
N  - NO 
P  - PRESENT 
A  - ABSENT 
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